fda pulling semaglutide U.S. finds no evidence yet linking weight-loss drugs to suicidal thoughts FDA's Removal of Semaglutide and

Proper dosage, consistent administration, and ongoing medical guidance ensure safety and maximize benefits

Meet the experts Related content and resources As consumers adopt GLP-1 medications and shift toward smaller, nutrient-dense meals, the demand for high-protein, fiber-rich and clean-label products with less sugar is accelerating

Weight loss can also improve OSA in patients with obesity or overweight as seen with the FDA approval of tirzepatide (Zepbound) and in clinical trials of the investigational GLP-1 agent orforglipron

Implications for Consumption Trends Sugar consumption is notoriously difficult to model and analyse